Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
EB
EUROFINS BIOPHARMA PRODUCT TESTING DENMARK A/S
aktivCVR 29428689AktieselskabSmedeskovvej 38, 8464 GaltenKontrol af levnedsmidler
- Latest accounts
- 2025
- Statement scope
- Standalone
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Not available from the published filing—
Not available from the published filing
Operating profit
DKK 14.1m
Latest period
Source details
Source: dk-regnskabsdata-live-29428689-1793894101615
Document: dk-regnskabsdata-29428689-AZ6mqmonHpprI11O9FJf-1
XBRL: fsa:ProfitLossFromOrdinaryOperatingActivities
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: ctx-1
Unit: dkk
Net result
DKK 10.2m
Latest period
Source details
Source: dk-regnskabsdata-live-29428689-1793894101615
Document: dk-regnskabsdata-29428689-AZ6mqmonHpprI11O9FJf-1
XBRL: fsa:ProfitLoss
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: ctx-1
Unit: dkk
Equity
DKK 23m
Equity ratio: 28.6%
Source details
Source: dk-regnskabsdata-live-29428689-1793894101615
Document: dk-regnskabsdata-29428689-AZ6mqmonHpprI11O9FJf-1
XBRL: fsa:Equity
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: ctx-10
Unit: dkk
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2023 | — | DKK 1.2m |
| 2024 | — | DKK 10.7m |
| 2025 | — | DKK 10.2m |